Cancer Precision-Prevention trial of Metformin in adults with Li Fraumeni syndrome (MILI) undergoing yearly MRI surveillance: a randomised controlled trial protocol.

doi:10.1186/s13063-024-07929-w

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Cancer Precision-Prevention trial of Metformin in adults with Li Fraumeni syndrome (MILI) undergoing yearly MRI surveillance: a randomised controlled trial protocol.

Trials - 3 Feb 2024

Dixon-Zegeye Miriam, Shaw Rachel, Collins Linda, Perez-Smith Kendra, Ooms Alexander, Qiao Maggie, Pantziarka Pan, Izatt Louise, Tischkowitz Marc, Harrison Rachel E, George Angela, Woodward Emma R, Lord Simon, Hawkes Lara, Evans D Gareth, Franklin James, Hanson Helen, Blagden Sarah P

Abstract excerpt

BACKGROUND: Li-Fraumeni syndrome (LFS) is a rare autosomal dominant disease caused by inherited or de novo germline pathogenic variants in TP53. Individuals with LFS have a 70-100% lifetime risk of developing cancer. The current standard of care involves annual surveillance with whole-body and brain MRI (WB-MRI) and clinical review; however, there are no chemoprevention agents licensed for individuals with LFS....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clinical Trials, Phase II as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Germ-Line Mutation

Share to Li-Fraumeni Syndrome

Share to Magnetic Resonance Imaging

Share to Metformin

Share to Mice

Share to Quality of Life

Share to Randomized Controlled Trials as Topic

Source

Open in PubMed Open full text

Identifiers

PMID: 38308321
DOI: 10.1186/s13063-024-07929-w
PMCID: PMC10837926

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cancer Precision-Prevention trial of Metformin in adults with Li Fraumeni syndrome (MILI) undergoing yearly MRI surveillance: a randomised controlled trial protocol.PMID 38308321Read ↗

Rates of Intervention and Cancer Detection on Initial versus Subsequent Whole-body MRI Screening in Li-Fraumeni Syndrome.Semantic proximity Read ↗

Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging: A Meta-analysis.Semantic proximity Read ↗

Update on Cancer Screening Recommendations for Individuals with Li–Fraumeni SyndromeSemantic proximity Read ↗

New Paradigms in the Clinical Management of Li-Fraumeni Syndrome.Semantic proximity Read ↗

Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational studySemantic proximity Read ↗

Li-Fraumeni Syndrome: Imaging Features and GuidelinesSemantic proximity Read ↗

Whole body magnetic resonance imaging (WB-MRI) and brain MRI baseline surveillance in TP53 germline mutation carriers: experience from the Li-Fraumeni Syndrome Education and Early Detection (LEAD) clinic.Semantic proximity Read ↗

Surveillance recommendations for patients with germline TP53 mutations.Semantic proximity Read ↗

Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study.Semantic proximity Read ↗

Li-Fraumeni Syndrome: An In-depth OverviewSemantic proximity Read ↗

Update on Whole-Body MRI Surveillance for Pediatric Cancer Predisposition Syndromes.Semantic proximity Read ↗

Pancreatic Cancer Risk and Screening Outcomes in Li-Fraumeni Syndrome.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.